View in EDS

Sleep effects in drug-resistant epileptic patients taking perampanel: an observational study.

Saved in:
Bibliographic Details
Title: Sleep effects in drug-resistant epileptic patients taking perampanel: an observational study.
Authors: Lamanna, Fabio (AUTHOR), Pardeo, Orazio (AUTHOR), Tilenni, Diana (AUTHOR), Luppino, Francesco (AUTHOR), Salafica, Giuseppe (AUTHOR), Barbaccia, Adele (AUTHOR), Laganà, Angelina (AUTHOR), Aricò, Irene (AUTHOR), Raineri, Serena (AUTHOR), Tripepi, Giovanni (AUTHOR), Silvestri, Rosalia (AUTHOR), Labate, Angelo (AUTHOR)
Source: Neurological Sciences. Jan2026, Vol. 47 Issue 1, p1-10. 10p.
Abstract: Background: Perampanel (PER) is a selective non-competitive antagonist of the AMPA receptor. While its efficacy in epilepsy very limited studies have focused on its impact on sleep quality, thus the aim of this study was to assess PER impact on sleep among patients with refractory epilepsy. Methods: Patients were recruited at the Epilepsy Center of the University of Messina, Italy according to the ILAE criteria and received PER as an add-on therapy. Sleep quality (PSQI), daytime sleepiness (ESS), and quality of life (QOLIE-31) were assessed at baseline and follow-up. Efficacy was evaluated based on seizure frequency reduction and classified as worsened, unchanged, < 50% improvement, ≥ 50% improvement, or seizure-free. Patients were also stratified by use of perampanel as first or late add-on therapy. Tolerability was assessed through reported adverse events. Results: Thirty-one patients were followed for six months; one was excluded due to seizure worsening. PER was first add-on in 11 patients, late add-on in 20. Sleep quality and daytime sleepiness showed slight improvement. QOLIE-31 scores showed a mild, non-significant improvement in quality of life, with a significant reduction in seizure worry in late add-on patients. In the first group, 100% were responders (≥ 50% seizure reduction), 27.2% seizure-free. In the late add-on group, 65% were responders, 30% seizure-free (p = 0.043). PER was well tolerated with no severe adverse events. Significance: PER appears to preserve sleep quality and mildly improve quality of life. Furthermore, PER shows greater efficacy when used as a first add-on therapy in drug-resistant epilepsy. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 190870874
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sleep effects in drug-resistant epileptic patients taking perampanel: an observational study.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lamanna%2C+Fabio%22&quot;&gt;Lamanna, Fabio&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pardeo%2C+Orazio%22&quot;&gt;Pardeo, Orazio&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tilenni%2C+Diana%22&quot;&gt;Tilenni, Diana&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Luppino%2C+Francesco%22&quot;&gt;Luppino, Francesco&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Salafica%2C+Giuseppe%22&quot;&gt;Salafica, Giuseppe&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Barbaccia%2C+Adele%22&quot;&gt;Barbaccia, Adele&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lagan&#224;%2C+Angelina%22&quot;&gt;Lagan&#224;, Angelina&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Aric&#242;%2C+Irene%22&quot;&gt;Aric&#242;, Irene&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Raineri%2C+Serena%22&quot;&gt;Raineri, Serena&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tripepi%2C+Giovanni%22&quot;&gt;Tripepi, Giovanni&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Silvestri%2C+Rosalia%22&quot;&gt;Silvestri, Rosalia&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Labate%2C+Angelo%22&quot;&gt;Labate, Angelo&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Neurological+Sciences%22&quot;&gt;Neurological Sciences&lt;/searchLink&gt;. Jan2026, Vol. 47 Issue 1, p1-10. 10p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Perampanel (PER) is a selective non-competitive antagonist of the AMPA receptor. While its efficacy in epilepsy very limited studies have focused on its impact on sleep quality, thus the aim of this study was to assess PER impact on sleep among patients with refractory epilepsy. Methods: Patients were recruited at the Epilepsy Center of the University of Messina, Italy according to the ILAE criteria and received PER as an add-on therapy. Sleep quality (PSQI), daytime sleepiness (ESS), and quality of life (QOLIE-31) were assessed at baseline and follow-up. Efficacy was evaluated based on seizure frequency reduction and classified as worsened, unchanged, &lt; 50% improvement, ≥ 50% improvement, or seizure-free. Patients were also stratified by use of perampanel as first or late add-on therapy. Tolerability was assessed through reported adverse events. Results: Thirty-one patients were followed for six months; one was excluded due to seizure worsening. PER was first add-on in 11 patients, late add-on in 20. Sleep quality and daytime sleepiness showed slight improvement. QOLIE-31 scores showed a mild, non-significant improvement in quality of life, with a significant reduction in seizure worry in late add-on patients. In the first group, 100% were responders (≥ 50% seizure reduction), 27.2% seizure-free. In the late add-on group, 65% were responders, 30% seizure-free (p = 0.043). PER was well tolerated with no severe adverse events. Significance: PER appears to preserve sleep quality and mildly improve quality of life. Furthermore, PER shows greater efficacy when used as a first add-on therapy in drug-resistant epilepsy. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=190870874
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-025-08785-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 1
    Titles:
      – TitleFull: Sleep effects in drug-resistant epileptic patients taking perampanel: an observational study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lamanna, Fabio
      – PersonEntity:
          Name:
            NameFull: Pardeo, Orazio
      – PersonEntity:
          Name:
            NameFull: Tilenni, Diana
      – PersonEntity:
          Name:
            NameFull: Luppino, Francesco
      – PersonEntity:
          Name:
            NameFull: Salafica, Giuseppe
      – PersonEntity:
          Name:
            NameFull: Barbaccia, Adele
      – PersonEntity:
          Name:
            NameFull: Laganà, Angelina
      – PersonEntity:
          Name:
            NameFull: Aricò, Irene
      – PersonEntity:
          Name:
            NameFull: Raineri, Serena
      – PersonEntity:
          Name:
            NameFull: Tripepi, Giovanni
      – PersonEntity:
          Name:
            NameFull: Silvestri, Rosalia
      – PersonEntity:
          Name:
            NameFull: Labate, Angelo
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 47
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1